• Therma Bright (THRM) has secured a partnership with K-One MediTech to manufacture and market the AcuVid COVID-19 Rapid Antigen Saliva Test Kit
  • Under this agreement, K-One MediTech will act as the primary manufacturer in Asia
  • The K-One MediTech manufacturing agreement encompasses development, designs, concepts, formulation, and manufacturing
  • K-One MediTech, a wholly-owned subsidiary of K-One Tech, is focused on the development and manufacturing of medical and healthcare products
  • Therma Bright is a progressive medical device technology company
  • Therma Bright (THRM) opened trading at C$0.385 per share

Therma Bright (THRM) has secured a partnership with K-One MediTech to bring the Acuvid™ COVID-19 Rapid Antigen Saliva Test Kit to the marketplace.

Under this agreement, K-One MediTech will act as the primary manufacturer in Asia to produce the AcuVid™ COVID-19 Rapid Antigen Saliva Test Kits. The term of the agreement will be for a two-year period, commencing from the first production batch of the AcuVid™ test kits for the Point-of-Care commercial market.

Rob Fia, CEO of Therma Bright, commented,

“With our primary Asia-based manufacturing partner, K-One MediTech, in place we are ready to begin production of our CE-approved AcuVid™ COVID-19 Rapid Antigen Saliva Test. Therma Bright will be able to add FDA Emergency Authorization Use (FDA-EUA) and Health Canada (HC) approved kits once regulatory approvals are secured.”

In April 2020, Therma Bright began developing its AcuVid™ COVID-19 Rapid Antigen Saliva Test using lateral flow technology. The company continues to test the saliva-based solution to meet and exceed FDA-EUA and Health Canada criteria. Testing will take place in Canada, once the company receives Health Canada approval.

Testing is currently taking place in Brazil. The Brazilian team has not only successfully detected the original novel coronavirus Wuhan strain (SARS CoV-2), but also the Brazilian P.1 and P.2 and the UK B.1.1.7 variants with the COVID-19 Rapid Antigen Saliva Test.

In addition to selecting the manufacturing partner for Asia, ThermaBright has introduced an easier, more accurate and less expensive version of AcuVid™. This development both simplifies the process for medical professionals and individuals administering or taking the AcuVid™ test and enables ThermaBright to significantly reduce its cost from the first prototype version.

The K-One MediTech development and manufacturing agreement will provide services including development, designs, concepts, formulation, and manufacturing for Therma Bright’s new AcuVid™ Covid-19 Rapid Antigen Saliva Test. K-One MediTech will be granted the primary manufacturer rights for Asia of the Company’s AcuVid™ COVID-19 Rapid Antigen Saliva Test Kits for a period of two years commencing from the 1st production batch for the commercial market.

Martin Lim, CEO of K-One MediTech, commented,

“We are pleased to be selected as Therma Bright’s primary manufacturer for Asia for its innovative AcuVid™ COVID-19 Rapid Antigen Saliva Test. This COVID-19 pandemic has devastated our communities. It has affected our loved ones with death and sickness and economic despair. Being part of a rapid testing solution, like AcuVid™, can assist citizens around the world to pursue twice-weekly serial testing regiments, while awaiting vaccinations. We’re honored to be a part of Therma Bright’s solution.”

K-One MediTech is a wholly-owned subsidiary of K-One Tech. Its principal focus is on the development and manufacturing of medical and healthcare products including medical devices, healthcare consumables, oral care gadgets and hospital equipment.

Therma Bright is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with innovative solutions that address some of today’s most important medical and healthcare challenges.

Therma Bright (THRM) opened trading at C$0.385 per share.

More From The Market Online

Usha Resources begins phase 4 fieldwork at White Willow Project

Usha Resources (TSXV:USHA) has begun the fourth phase of fieldwork at its White Willow Lithium Project in Ontario following phase 3 work.

@ the Bell: Stocks level-out ahead of Easter long weekend

A rebound in oil prices and growth in metal prices helped push Canada’s main stock index higher as investors await economic data.